REVIEW   Free access

Minerva Gastroenterology 2024 September;70(Suppl. 1 to N. 3):1-7

DOI: 10.23736/S2724-5985.24.03826-9

Copyright © 2024 EDIZIONI MINERVA MEDICA

language: English

Twenty-five percent human albumin solution in clinical practice: indications, risks and monitoring protocols

Carmine GAMBINO, Paolo ANGELI ✉

Unit of Internal Medicine and Hepatology (UIMH), University-Teaching Hospital of Padua, Padua, Italy

Human albumin solution is a commonly used therapeutic agent because of its ability to expand plasma volume and improve oncotic pressure in various clinical settings, such as in patients with cirrhosis and sepsis, whose management is a major challenge. Despite the lack of evidence for the superiority of human albumin solutions compared with crystalloids in improving major outcomes, short-term administration of human albumin solution appears to be more effective than both saline and plasmalyte in recovering systemic hemodynamics and achieving a lower daily net fluid balance in patients with cirrhosis and sepsis-induced hypotension. The use of 25% human albumin solution could also effectively manage ascites in patients with cirrhosis, reducing the volume of fluids administered and allowing a faster achievement of the plasma target concentration. This article aims to comprehensively review the indications for the use of human albumin solutions, examine the associated risks, and outline best practices for monitoring patients receiving this treatment, ensuring optimal patient outcomes while minimizing adverse effects.

KEY WORDS: Albumins; Serum albumin, human; Liver cirrhosis; Sepsis